Laboratório de Inflamação e Biomarcadores, Instituto Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, Bahia, Brazil.
Multinational Organization Network Sponsoring Translational and Epidemiological Research (MONSTER) Initiative, Salvador, Bahia, Brazil.
PLoS One. 2021 Jan 4;16(1):e0241096. doi: 10.1371/journal.pone.0241096. eCollection 2021.
Neurofibromatosis type 1 (NF-1) is an autosomal dominant disease that affects one in every 3000 individuals. This disease can present a wide range of clinical manifestations, ranging from skin abnormalities to severe vascular damage. Although not commonly recognized in the context of NF-1, cerebrovascular disease (CVD), can be often present since childhood and diagnosed just later in life. When present, NF-1-associated CVD clinical manifestations may include headache, cognitive deficits and ultimately aneurysm rupture, causing death. Thus, CVD plays an important role in the clinical manifestations, disease severity and prognosis of patients with NF-1. This systematic review aims to summarize the body of evidence linking NF-1 and CVD in children.
Two independent investigators performed a systematic review on the PubMed and EMBASE search platforms, using the following key terms: "neurofibromatosis type 1", "Von Recklinghausen's disease", "children", "adolescents", "stroke", "Moyamoya disease", "vascular diseases", "cerebrovascular disorders", "aneurysm" and "congenital abnormalities". Studies focused on assessing the development of CVD in children with NF-1 were included.
Seven studies met the inclusion criteria. Twelve different clinical manifestations have been associated with cerebrovascular changes in children with NF-1; 44,5% of diagnosed patients were asymptomatic.
The available evidence suggests that CVDs are related with the progression of NF-1, even in the absence of a clear clinical manifestation. In addition, improved prognosis was observed when imaging tests were performed to screen for cerebrovascular alterations early during the clinical investigation. Early diagnosis of CVD in NF-1 patients foster implementation of timely interventions, directly impacting clinical outcomes.
神经纤维瘤病 1 型(NF-1)是一种常染色体显性遗传病,每 3000 个人中就有 1 人患病。这种疾病可以表现出广泛的临床表现,从皮肤异常到严重的血管损伤。尽管在 NF-1 中并不常见,但脑血管疾病(CVD)可能自童年起就经常存在,并在以后的生活中被诊断出来。当存在时,NF-1 相关的 CVD 临床表现可能包括头痛、认知缺陷,最终导致动脉瘤破裂,导致死亡。因此,CVD 在 NF-1 患者的临床表现、疾病严重程度和预后中起着重要作用。本系统评价旨在总结 NF-1 与儿童 CVD 相关的证据。
两名独立的调查员在 PubMed 和 EMBASE 搜索平台上进行了系统评价,使用了以下关键词:“神经纤维瘤病 1 型”、“冯·雷克林豪森氏病”、“儿童”、“青少年”、“中风”、“烟雾病”、“血管疾病”、“脑血管疾病”、“动脉瘤”和“先天性异常”。纳入的研究重点评估了 NF-1 儿童 CVD 的发展情况。
符合纳入标准的研究有 7 项。12 种不同的临床表现与 NF-1 儿童的脑血管变化有关;诊断出的患者中有 44.5%无症状。
现有证据表明,CVD 与 NF-1 的进展有关,即使没有明显的临床表现也是如此。此外,在临床研究早期进行影像学检查以筛查脑血管改变时,观察到预后改善。NF-1 患者 CVD 的早期诊断促进了及时干预措施的实施,直接影响临床结果。